Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylases 1, 2, 3, and 8 are zinc-dependent enzymes belonging to Class I histone deacetylases. They catalyze the removal of acetyl groups from the lysine residues on the N-terminal tails of core histones, leading to chromatin condensation and transcriptional repression. These enzymes play a pivotal role in the regulation of gene expression, epigenetic silencing, and cellular differentiation. Their dysregulation is implicated in various diseases, notably cancer, making them important targets for small-molecule inhibitors. In addition to histone substrates, Class I HDACs also deacetylate several non-histone proteins, influencing diverse cellular processes including cell cycle, apoptosis, and DNA repair.
Inhibition of histone deacetylase activity Induction of histone hyperacetylation Reactivation of silenced genes (including tumor suppressors) Promotion of cell cycle arrest and apoptosis in cancer cells Modulation of immune response
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone deacetylase 1, 2, 3, and 8 (HDAC1, HDAC2, HDAC3, HDAC8).